Last updated: 2026-09-06 02:54:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Intellia Therapeutics, Inc. (NTLA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $12.75, with a market capitalization of $1.79B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.95 to $28.25. This page covers its latest market performance, valuation, price trends and company information.
$1.79B | |
$12.59 | |
$202.73 | |
$5.90 | |
$12.68 | |
2.48M | |
-- | |
-- | |
$28.25 | |
$7.95 | |
-- | |
-- |
Intellia Therapeutics, Inc. (NTLA) last closed at $12.68 as of 2026-09-04 23:59:00, unchanged from the previous close of $12.68.
During the latest regular trading session, NTLA traded between $5.90 and $202.73, with a volume of 2.48M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Intellia Therapeutics, Inc. (NTLA) moved from $12.64 to $12.75, representing a gain of 0.89% ($0.11).
The stock traded between $12.54 and $12.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.86 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.7%
NTLA is currently trading at $12.75, placing it 23.7% of the way from its 52-week low of $7.95 to its 52-week high of $28.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 377 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Intellia Therapeutics, Inc. (NTLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.